The use of PEGylated liposomes in the development of drug delivery applications for the treatment of hemophilia

References

• DahlbackBBlood coagulation and its regulation by anticoagulant pathways: genetic pathogenesis of bleeding and thrombotic diseasesJ Intern Med200525720922315715678
   PubMed Web of Science ®Google Scholar
• HednerUGinsburgDLusherJMHighKACongenital Hemorrhagic Disorders: New Insights into the Pathophysiology and Treatment of HemophiliaHematology Am Soc Hematol Educ Program200024126511701545
   PubMedGoogle Scholar
• SoucieJMEvattBJacksonDOccurrence of hemophilia in the United States. The Hemophilia Surveillance System Project InvestigatorsAm J Hematol1998592882949840909
   PubMed Web of Science ®Google Scholar
• KaufmanRJAnthonorakisSEFayPJHemostasis and Thrombosis: Basic Principles and Clinical Practice4th edPhiladelphiaLippincott Williams and Wilkins2001
   Google Scholar
• RoosendaalGMauser-BunschotenEPDe KleijnPSynovium in haemophilic arthropathyHaemophilia199845025059873782
   PubMed Web of Science ®Google Scholar
• ArunBKesslerCColmanWHirshJMarderVClowesAGeorgeJInherited hemorrhagic disordersHemostasis and thrombosis4th edPhiladelphiaLippincott Williams & Willkins2001815825
   Google Scholar
• HootsWKNugentDJEvidence for the benefits of prophylaxis in the management of hemophilia AThromb Haemost20069643344017003919
   PubMed Web of Science ®Google Scholar
• KesslerCMNew perspectives in hemophilia treatmentHematology Am Soc Hematol Educ Program200542943516304415
   PubMedGoogle Scholar
• JankowskiMAPatelHRouseJCMarzilliLAWestonSBSharpePJDefining ‘full-length’ recombinant factor VIII: a comparative structural analysisHaemophilia200713303717212722
   PubMed Web of Science ®Google Scholar
• FijnvandraatKBerntorpEten CateJWRecombinant, B-domain deleted factor VIII (r-VIII SQ): pharmacokinetics and initial safety aspects in hemophilia A patientsThromb Haemost1997772983029157585
   PubMed Web of Science ®Google Scholar
• WeissHJSussmanIIHoyerLWStabilization of factor VIII in plasma by the von Willebrand factor. Studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand’s diseaseJ Clin Invest19776039040417621
   PubMed Web of Science ®Google Scholar
• SantagostinoEMancusoMEBarriers to primary prophylaxis in haemophilic children: the issue of the venous accessBlood Transfus20086S121619105504
   PubMedGoogle Scholar
• SaenkoELAnanyevaNMMoayeriMRamezaniAHawleyRGDevelopment of improved factor VIII molecules and new gene transfer approaches for hemophilia ACurr Gene Ther20033274112553533
   PubMedGoogle Scholar
• MathewPCurrent opinion on inhibitor treatment optionsSemin Hematol200643S81316690374
   PubMed Web of Science ®Google Scholar
• LusherJMRobertsHRDavignonGA randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study GroupHaemophilia1998479079810028299
   PubMed Web of Science ®Google Scholar
• ShapiroAInhibitor treatment: state of the artDis Mon200349223812525826
   PubMed Web of Science ®Google Scholar
• RickMEWalshCEKeyNSCongenital bleeding disordersHematology Am Soc Hematol Educ Program200355957414633799
   PubMedGoogle Scholar
• ZeitlerHUlrich-MerzenichGHessLTreatment of acquired hemophilia by the Bonn-Malmo Protocol: documentation of an in vivo immunomodulating conceptBlood20051052287229315542586
   PubMed Web of Science ®Google Scholar
• MaADCarrizosaDAcquired factor VIII inhibitors: pathophysiology and treatmentHematology Am Soc Hematol Educ Program200643243717124095
   PubMedGoogle Scholar
• KemptonCLWhiteGC2ndHow we treat a hemophilia A patient with a factor VIII inhibitorBlood2009113111718820129
   PubMed Web of Science ®Google Scholar
• TjonnfjordGEHolmePAFactor eight inhibitor bypass activity (FEIBA) in the management of bleeds in hemophilia patients with high-titer inhibitorsVasc Health Risk Manag2007352753117969383
   PubMedGoogle Scholar
• HednerUGlazerSPingelKSuccessful use of recombinant factor VIIa in patient with severe haemophilia A during synovectomyLancet1988211932903400
   PubMed Web of Science ®Google Scholar
• IngerslevJEfficacy and safety of recombinant factor VIIa in the prophylaxis of bleeding in various surgical procedures in hemophilic patients with factor VIII and factor IX inhibitorsSemin Thromb Hemost20002642543211092219
   PubMed Web of Science ®Google Scholar
• FridbergMJHednerURobertsHRErhardtsenEA study of the pharmacokinetics and safety of recombinant activated factor VII in healthy Caucasian and Japanese subjectsBlood Coagul Fibrinolysis20051625926615870545
   PubMed Web of Science ®Google Scholar
• LindleyCMSawyerWTMacikBGPharmacokinetics and pharmacodynamics of recombinant factor VIIaClin Pharmacol Ther1994556386488004880
   PubMed Web of Science ®Google Scholar
• IngerslevJThykjaerHKudsk JensenOFredbergUHome treatment with recombinant activated factor VII: results from one centreBlood Coagul Fibrinolysis19989S1071109819039
   PubMed Web of Science ®Google Scholar
• KeyNSAledortLMBeardsleyDHome treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novo-seven) in haemophiliacs with inhibitorsJ Thromb Haemost199880912918
   Google Scholar
• SaenkoELPipeSWStrategies towards a longer acting factor VIIIHaemophilia200612Suppl 3425116683996
   PubMed Web of Science ®Google Scholar
• GaleAJPellequerJLAn engineered interdomain disulfide bond stabilizes human blood coagulation factor VIIIaJ Thromb Haemost200311966197112941038
   PubMed Web of Science ®Google Scholar
• GaleAJRadtkeKPCunninghamMAChamberlainDPellequerJLGriffinJHIntrinsic stability and functional properties of disulfide bond-stabilized coagulation factor VIIIa variantsJ Thromb Haemost200641315213216706977
   PubMed Web of Science ®Google Scholar
• PipeSWKaufmanRJCharacterization of a genetically engineered inactivation-resistant coagulation factor VIIIaProc Natl Acad Sci U S A19979411851118569342326
   PubMed Web of Science ®Google Scholar
• MeiBPanCJiangHRational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatmentBlood
   Web of Science ®Google Scholar
• MurphyJEPanCBarnettTSite-specific PEGylation of rFVIII results in prolonged in vivo efficacyJ Thromb Haemost20075P-T-022
   Google Scholar
• ReganLMJiangXRamseyPBiological activity of PEGylated factor VIIIJ Thromb Haemost20075P-T-026
   Google Scholar
• TangLPanCAtwalHPEGylation protects factor VIII from the inhibition of antibody inhibitorsJ Thromb Haemost20075P-T-036
   Google Scholar
• AllenGAPerssonECampbellRAEzbanMHednerUWolbergASA variant of recombinant factor VIIa with enhanced procoagulant and antifibrinolytic activities in an in vitro model of hemophiliaArterioscler Thromb Vasc Biol20072768368917204663
   PubMed Web of Science ®Google Scholar
• StennickeHROstergaardHBayerRJGeneration and biochemical characterization of glycoPEGylated factor VIIa derivativesJ Thromb Haemost2008100920928
   Web of Science ®Google Scholar
• SchulteSUse of albumin fusion technology to prolong the half-life of recombinant factor VIIaThromb Res2008122S141918929521
   PubMed Web of Science ®Google Scholar
• ZamboniWCConcept and clinical evaluation of carrier-mediated anticancer agentsOncologist20081324826018378535
   PubMed Web of Science ®Google Scholar
• ElbayoumiTATorchilinVPLiposomes for targeted delivery of antithrombotic drugsExpert Opin Drug Deliv200851185119818976130
   PubMed Web of Science ®Google Scholar
• GabizonAShmeedaHBarenholzYPharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studiesClin Pharmacokinet20034241943612739982
   PubMed Web of Science ®Google Scholar
• GabizonACataneRUzielyBProlonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomesCancer Res1994549879928313389
   PubMed Web of Science ®Google Scholar
• GabizonAABarenholzYBialerMProlongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycol-derivatized phospholipid: pharmacokinetic studies in rodents and dogsPharm Res1993107037088321835
   PubMed Web of Science ®Google Scholar
• KlibanovALMaruyamaKTorchilinVPHuangLAmphipathic polyethyleneglycols effectively prolong the circulation time of liposomesFEBS Lett19902682352372384160
   PubMed Web of Science ®Google Scholar
• BaruMCarmel-GorenLBarenholzYFactor VIII efficient and specific non-covalent binding to PEGylated liposomes enables prolongation of its circulation time and haemostatic efficacyJ Thromb Haemost20059310611068
   Google Scholar
• DayanIRobinsonMBaruMEnhancement of haemostatic efficacy of plasma-derived FVIII by formulation with PEGylated liposomesHaemophilia2009151006101319486171
   PubMed Web of Science ®Google Scholar
• YatuvRDayanICarmel-GorenLEnhancement of factor VIIa haemostatic efficacy by formulation with PEGylated liposomesHaemophilia20081447648318393980
   PubMed Web of Science ®Google Scholar
• YatuvRCarmel-GorenLDayanIRobinsonMBaruMBinding of proteins to PEGylated liposomes and improvement of G-CSF efficacy in mobilization of hematopoietic stem cellsJ Control Release2009135445019135487
   PubMed Web of Science ®Google Scholar
• SpiraJPlyushchOPAndreevaTAAndreevYProlonged bleeding-free period following prophylactic infusion of recombinant factor VIII reconstituted with pegylated liposomesBlood20061083668367316888098
   PubMed Web of Science ®Google Scholar
• PanJLiuTKimJYEnhanced efficacy of recombinant FVIII in noncovalent complex with PEGylated liposome in hemophilia A miceBlood20091142802281119654409
   PubMed Web of Science ®Google Scholar
• PowellJSLiposomal approach towards the development of a longer-acting factor VIIIHaemophilia200713232817685920
   PubMed Web of Science ®Google Scholar
• SpiraJPlyushchOPAndreevaTAKhametovaRNEvaluation of liposomal dose in recombinant factor VIII reconstituted with pegylated liposomes for the treatment of patients with severe haemophilia AJ Thromb Haemost2008100429434
   Web of Science ®Google Scholar
• PowellJSNugentDJHarrisonJASafety and pharmacokinetics of a recombinant factor VIII with pegylated liposomes in severe hemophilia AJ Thromb Haemost2008627728318039351
   PubMed Web of Science ®Google Scholar
• MartinowitzULalezariSLuboshitzJLubetskyASpiraJInfusion rates of recombinant FVIII-FS with PEGylated liposomes in haemophilia AHaemophilia2008141122112418564190
   PubMed Web of Science ®Google Scholar
• SzebeniJComplement activation-related pseudoallergy: a new class of drug-induced acute immune toxicityToxicology200521610612116140450
   PubMed Web of Science ®Google Scholar
• SpiraJPlyushchOPZozulyaNSafety, pharmacokinetics and efficacy of factor VIIa formulated with PEGylated liposomes in haemophilia A patients with inhibitors to factor VIII. An open label, exploratory, cross over, phase I/II studyHaemophilia2010 In Press
   Web of Science ®Google Scholar
• YatuvRRobinsonMDayanIBaruMEnhancement of the efficacy of therapeutic proteins by formulation with PEGylated liposomes; a case of FVIII, FVIIa and G-CSFExpert Opin Drug Deliv2010718720120095942
   PubMed Web of Science ®Google Scholar
• ConstantinescuILevinEGyongyossy-IssaMLiposomes and blood cells: a flow cytometric studyArtif Cells Blood Substit Immobil Biotechnol20033139542414672416
   PubMed Web of Science ®Google Scholar
• HighKAThe leak stops here: platelets as delivery vehicles for coagulation factorsJ Clin Invest20061161840184216823486
   PubMed Web of Science ®Google Scholar
• LaubRDi GiambattistaMFonduPInhibitors in German hemophilia A patients treated with a double virus inactivated factor VIII concentrate bind to the C2 domain of FVIII light chainJ Thromb Haemost1999813944
   Google Scholar
• RautSDi GiambattistaMBevanSAHubbardARBarrowcliffeTWLaubRModification of factor VIII in therapeutic concentrates after virus inactivation by solvent-detergent and pasteurisationJ Thromb Haemost199880624631
   Google Scholar
• KanterPMBullardGAPilkiewiczFGMayerLDCullisPRPavelicZPPreclinical toxicology study of liposome encapsulated doxorubicin (TLC D-99): comparison with doxorubicin and empty liposomes in mice and dogsIn Vivo1993785958504212
   PubMedGoogle Scholar